CLINICAL ROLE -
Aggressive lipid lowering superior to usual care in a real-world setting: The ALLIANCE study
dual path
Exam
Dual inhibition effective and safe in clinical practice: The EASE study
Managed Care Commentary:MCOs face new challenges
Phytosterols may play role in atherosclerosis
Blocking intestinal cholesterol absorption for optimal lipid lowering
Dual pathway inhibition: Attacking cholesterol on two fronts
Beyond ATP III-Impact of recent clinical trials on future lipid management guidelines and therapeutic goals
Future Goals, Targets, and Treatments of Dyslipidemia
